Illumina, Inc. (NASDAQ:ILMN) Shares Purchased by Creative Planning

Posted by Defense World Staff on Oct 11th, 2023

Creative Planning boosted its holdings in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 16.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,118 shares of the life sciences company’s stock after acquiring an additional 1,968 shares during the period. Creative Planning’s holdings in Illumina were worth $2,647,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the business. HighMark Wealth Management LLC acquired a new stake in shares of Illumina during the 1st quarter worth about $33,000. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Illumina during the 1st quarter worth about $33,000. Clearstead Trust LLC lifted its holdings in shares of Illumina by 125.7% during the 1st quarter. Clearstead Trust LLC now owns 158 shares of the life sciences company’s stock worth $37,000 after acquiring an additional 88 shares during the period. BOKF NA purchased a new position in shares of Illumina during the 1st quarter worth about $38,000. Finally, WealthPLAN Partners LLC purchased a new position in shares of Illumina during the 1st quarter worth about $42,000. 92.17% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ILMN. Piper Sandler cut their price objective on shares of Illumina from $290.00 to $275.00 and set an “overweight” rating on the stock in a report on Tuesday, August 15th. Royal Bank of Canada cut their price objective on shares of Illumina from $337.00 to $328.00 and set an “outperform” rating on the stock in a report on Tuesday, August 8th. Citigroup cut their price objective on shares of Illumina from $180.00 to $150.00 and set a “sell” rating on the stock in a report on Thursday, August 10th. Bank of America cut their price target on shares of Illumina from $230.00 to $210.00 in a report on Thursday, August 10th. Finally, StockNews.com began coverage on shares of Illumina in a report on Thursday, October 5th. They issued a “hold” rating on the stock. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, Illumina has an average rating of “Hold” and a consensus target price of $222.85.

Read Our Latest Stock Analysis on ILMN

Illumina Stock Up 0.7 %

ILMN stock opened at $138.79 on Wednesday. Illumina, Inc. has a twelve month low of $127.37 and a twelve month high of $248.87. The company has a current ratio of 1.40, a quick ratio of 1.13 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $21.97 billion, a P/E ratio of -5.22, a PEG ratio of 7.58 and a beta of 1.16. The firm has a 50 day simple moving average of $156.96 and a 200-day simple moving average of $187.42.

Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings results on Wednesday, August 9th. The life sciences company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.30. Illumina had a negative net margin of 93.86% and a positive return on equity of 1.97%. The business had revenue of $1.18 billion during the quarter, compared to the consensus estimate of $1.16 billion. During the same quarter last year, the company earned $0.57 earnings per share. The business’s quarterly revenue was up 1.2% compared to the same quarter last year. On average, equities research analysts predict that Illumina, Inc. will post 0.83 earnings per share for the current fiscal year.

Insider Transactions at Illumina

In other Illumina news, SVP Susan H. Tousi sold 500 shares of Illumina stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $167.04, for a total value of $83,520.00. Following the completion of the transaction, the senior vice president now owns 45,524 shares of the company’s stock, valued at $7,604,328.96. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.13% of the company’s stock.

About Illumina

(Free Report)

Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.